In luminal disease, structure-guided optimization has accelerated the development of next-generation oral SERDs, such as elacestrant and camizestrant, which have demonstrated clinical benefit in patients with ESR1-mutant advanced breast cancer [15,16,17,18,19]. This evidence concerns the gene ESR1 and breast carcinoma.